Clinical Trial Update: Blocking Extracellular Galectin-3 in Patients With Osteoarthritis [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating a therapy that blocks extracellular Galectin-3 in osteoarthritis patients; the update provides no results or current status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoarthritis

Drugs mentioned

• Galectin-3 extracellular blocker (galectin-3 inhibitor)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Osteoarthritis | Phase 3 | Status: UNKNOWN